FR08C0039I2 - AZAPOLYCYCLIC COMPOUNDS FUSED WITH AN ARYL - Google Patents

AZAPOLYCYCLIC COMPOUNDS FUSED WITH AN ARYL

Info

Publication number: FR08C0039I2
Authority: FR; France
Prior art keywords: aryl; compounds fused; azapolycyclic compounds; azapolycyclic; fused
Prior art date: 1997-12-31
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR08C0039C

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pfizer Products Inc

Original Assignee

Pfizer Products Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-12-31

Filing date

2008-07-21

Publication date

2009-12-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22094096&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR08C0039(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-07-21 Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc

2008-11-14 Publication of FR08C0039I1 publication Critical patent/FR08C0039I1/fr

2009-12-18 Application granted granted Critical

2009-12-18 Publication of FR08C0039I2 publication Critical patent/FR08C0039I2/en

Status Active legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C07D221/24—Camphidines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/08—Bridged systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Addiction (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Epidemiology (AREA)
Obesity (AREA)
Hematology (AREA)
Diabetes (AREA)
Psychology (AREA)
Anesthesiology (AREA)
Hospice & Palliative Care (AREA)
Child & Adolescent Psychology (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Other In-Based Heterocyclic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

FR08C0039C 1997-12-31 2008-07-21 AZAPOLYCYCLIC COMPOUNDS FUSED WITH AN ARYL Active FR08C0039I2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US7024597P	1997-12-31	1997-12-31
PCT/IB1998/001813 WO1999035131A1 (en)	1997-12-31	1998-11-13	Aryl fused azapolycyclic compounds

Publications (2)

Publication Number	Publication Date
FR08C0039I1 FR08C0039I1 (en)	2008-11-14
FR08C0039I2 true FR08C0039I2 (en)	2009-12-18

Family

ID=22094096

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR08C0039C Active FR08C0039I2 (en)	1997-12-31	2008-07-21	AZAPOLYCYCLIC COMPOUNDS FUSED WITH AN ARYL

Country Status (51)

Country	Link
US (6)	US6410550B1 (en)
EP (2)	EP1659114A3 (en)
JP (1)	JP3550359B2 (en)
KR (1)	KR100408138B1 (en)
CN (2)	CN1715280A (en)
AP (1)	AP1170A (en)
AR (1)	AR017967A1 (en)
AT (1)	ATE386024T1 (en)
AU (1)	AU753389C (en)
BG (1)	BG65058B1 (en)
BR (2)	BR9816186B1 (en)
CA (1)	CA2316921C (en)
CO (1)	CO4810373A1 (en)
CY (2)	CY1107391T1 (en)
CZ (1)	CZ301925B6 (en)
DE (2)	DE69839131T3 (en)
DK (1)	DK1044189T4 (en)
DZ (1)	DZ2697A1 (en)
EA (1)	EA003190B1 (en)
EG (1)	EG23816A (en)
ES (1)	ES2301210T5 (en)
FR (1)	FR08C0039I2 (en)
GT (2)	GT199800200AA (en)
HN (1)	HN1998000177A (en)
HR (2)	HRP20000445B1 (en)
HU (2)	HU230297B1 (en)
IL (2)	IL136727A0 (en)
IS (1)	IS5514A (en)
LU (1)	LU91442I2 (en)
MA (1)	MA26589A1 (en)
ME (1)	ME00459B (en)
MY (1)	MY118163A (en)
NL (1)	NL300355I2 (en)
NO (2)	NO319115B1 (en)
NZ (1)	NZ504482A (en)
OA (1)	OA11428A (en)
PA (1)	PA8463901A1 (en)
PE (1)	PE20000053A1 (en)
PL (1)	PL209404B1 (en)
PT (1)	PT1044189E (en)
RS (1)	RS50069B (en)
SA (1)	SA99191123B1 (en)
SG (1)	SG102686A1 (en)
SI (1)	SI1044189T2 (en)
SK (1)	SK286886B6 (en)
TN (1)	TNSN98237A1 (en)
TR (1)	TR200001840T2 (en)
TW (1)	TW513412B (en)
UA (1)	UA66825C2 (en)
WO (1)	WO1999035131A1 (en)
ZA (1)	ZA9811911B (en)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ME00459B (en) *	1997-12-31	2011-10-10	Pfizer Prod Inc	Aryl fused azapolycyclic compounds
US6605610B1 (en) *	1997-12-31	2003-08-12	Pfizer Inc	Aryl fused azapolycyclic compounds
DE60040293D1 (en)	1999-07-28	2008-10-30	Univ R	USE OF NICOTIN IN THE ANGIOGENESIS AND THE VASCULOSIS
US8188043B2 (en)	1999-07-28	2012-05-29	The Board Of Trustees Of The Leland Stanford Jr. University	Nicotine in therapeutic angiogenesis and vasculogenesis
IL137937A0 (en) *	1999-08-27	2001-10-31	Pfizer Prod Inc	A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
US20020010192A1 (en) *	2000-06-02	2002-01-24	Coe Jotham Wadsworth	Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20020016334A1 (en) *	2000-07-31	2002-02-07	Coe Jotham Wadsworth	Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD)
YU78303A (en) *	2001-04-20	2006-05-25	Pfizer Products Inc.	Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds
PT1392307E (en) *	2001-05-14	2005-11-30	Pfizer Prod Inc	SALTS 5,8,14-TRIAZATETRACYCLO [10.3.1.02,11.04,9] -HEXADECA-2 (11), 3,5,7,9-PENTAENE
NZ528209A (en)	2001-05-14	2004-09-24	Pfizer Prod Inc	The citrate salt of 5, 8, 14-triazatetracyclo (10.3.1.02,11.04.9)-hexadeca-2.(11),3,5,7,9-pentaene
DE60209929T2 (en)	2001-11-29	2006-11-16	Pfizer Products Inc., Groton	SUCCINATE SALTS OF 58; 8; 14-TRIATETRACYCLO [10.3.1.0 2,11 .0 4,9] -HEXADECA-2,11,3,5,7,9-PENTAES AND PHARMACEUTICAL COMPOSITIONS
PT1448235E (en) *	2001-11-30	2007-05-31	Pfizer Prod Inc	Oral controlled release pharmaceutical compositions of 5,8,14-triazatetracyclo 10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene
RU2004116320A (en)	2001-11-30	2005-10-10	Пфайзер Продактс Инк. (Us)	Aryl-condensed azapolycyclic compounds
EP1572127B2 (en) *	2002-02-14	2014-10-29	The Board of Trustees of the Leland Stanford Junior University	Enzyme treatment of foodstuffs for celiac sprue
US7320788B2 (en) *	2002-02-14	2008-01-22	The Board Of Trustees Of The Leland Stanford Junior University	Enzyme treatment of foodstuffs for Celiac Sprue
US8143210B2 (en) *	2002-02-14	2012-03-27	The Board Of Trustees Of The Leland Stanford Junior University	Enzyme treatment of foodstuffs for celiac sprue
US7462688B2 (en) *	2002-05-14	2008-12-09	The Board Of Trustees Of The Leland Stanford Junior University	Peptides for diagnostic and therapeutic methods for celiac sprue
US7202216B2 (en) *	2002-05-14	2007-04-10	The Board Of Trustees Of The Leland Stanford Junior University	Drug therapy for celiac sprue
US7265093B2 (en) *	2002-05-14	2007-09-04	The Board Of Trustees Of The Leland Stanford Junior University	Drug therapy for Celiac Sprue
AU2003234634A1 (en) *	2002-05-14	2003-12-02	Felix Hausch	Drug therapy for celiac sprue
WO2004046077A1 (en)	2002-11-20	2004-06-03	Pfizer Products Inc.	A method for preparing indan-1,3-dicarboxylic acid
AU2003294473A1 (en) *	2002-11-20	2004-06-15	The Board Of Trustees Of The Leland Stanford Junior University	Diagnostic method for celiac sprue
AU2003278510B8 (en) *	2002-11-25	2008-07-10	Pfizer Products Inc.	Improved process for the preparation of 1,3-substituted indenes
EP1587794A1 (en) *	2003-01-15	2005-10-26	Pfizer Products Inc.	Process for the preparation of aryl fused polycyclic lactams
US20040224963A1 (en) *	2003-05-09	2004-11-11	Pfizer Inc	Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
US20040224962A1 (en) *	2003-05-09	2004-11-11	Pfizer Inc	Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
JP2006528237A (en) *	2003-05-20	2006-12-14	ファイザー・プロダクツ・インク	Pharmaceutical composition of varenicline
DK1638971T3 (en) *	2003-06-04	2008-10-27	Pfizer Prod Inc	Preparation of Substituted Quinoxalins from the Dianiline with 2,3-Dihydroxy-1,4-Dioxane
EP1648893B1 (en) *	2003-07-21	2009-09-23	Pfizer Products Inc.	Nicotine addiction reducing heteroaryl fused azapolycyclic compounds
JP2006528170A (en) *	2003-07-21	2006-12-14	ファイザー・プロダクツ・インク	Aryl-fused azapolycyclic compounds
US20050043407A1 (en) *	2003-08-22	2005-02-24	Pfizer Inc	Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US20050043406A1 (en) *	2003-08-22	2005-02-24	Pfizer Inc	Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US7579313B2 (en) *	2003-11-18	2009-08-25	The Board Of Trustees Of The Leland Stanford Junior University	Transglutaminase inhibitors and methods of use thereof
US7563864B2 (en) *	2004-04-26	2009-07-21	Celiac Sprue Research Foundation	Prolyl endopeptidase mediated destruction of T cell epitopes in whole gluten
US7534426B2 (en) *	2004-04-26	2009-05-19	The Board Of Trustees Of The Leland Stanford Junior University	Glutenase enzyme assays
US7628985B2 (en) *	2004-04-26	2009-12-08	The Board Of Regents Of The Leland Stanford Junior University	Therapeutic enzyme formulations and uses thereof in celiac sprue and/or dermatitis herpetoformis
WO2006006071A1 (en) *	2004-07-07	2006-01-19	Pfizer Products Inc.	Resolution of an aryl-fused azapolycyclic compound
US7766018B2 (en) *	2004-09-30	2010-08-03	Smoke-Break, Inc.	Device and composition for reducing the incidence of tobacco smoking
ES2313625T3 (en) *	2005-02-24	2009-03-01	Pfizer Products Incorporated	PREPARATION OF A HIGH PURITY REPLACED QUINOXALINE.
US20060211649A1 (en) *	2005-03-21	2006-09-21	Eric Marchewitz	Use of cytisine for enhancing physical performance
EP1976495A2 (en) *	2006-01-06	2008-10-08	Aarhus Universitet	Compounds acting on the serotonin transporter
CA2644448A1 (en) *	2006-03-27	2007-10-04	Pfizer Products Inc.	Varenicline standards and impurity controls
MX2008013606A (en) *	2006-04-24	2008-10-30	Pfizer Prod Inc	Asymmetric membranes for drug delivery devices.
EP2255848A3 (en)	2006-09-04	2011-04-06	NeuroSearch AS	Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
JP2010527907A (en) *	2006-11-09	2010-08-19	ファイザー・プロダクツ・インク	Polymorphs of nicotine-like intermediates
AU2008229448B2 (en) *	2007-03-16	2013-01-24	The Board Of Trustees Of The Leland Stanford Junior University	Combination enzyme therapy for digestion of dietary gluten
WO2009034431A2 (en)	2007-09-10	2009-03-19	Pfizer Inc.	Controlled-release dosage forms for varenicline
EP2260037A2 (en) *	2008-02-15	2010-12-15	Medichem, S.A.	A polymorphic form of a pyrazino [2,3-h] [3] benzazepine derivative
US20090215787A1 (en) *	2008-02-22	2009-08-27	Mai De Ltd.	Preparations of new polymorphic forms of varenicline tartrate
JP2011516489A (en) *	2008-03-31	2011-05-26	ユニバーシティ・オブ・サウス・フロリダ	Treatment of disease-induced ataxia and ataxia imbalance
EP2268639A2 (en) *	2008-05-22	2011-01-05	Teva Pharmaceutical Industries Ltd.	Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate
US20090318460A1 (en) *	2008-05-26	2009-12-24	Glenmark	Amorphous varenicline tartrate and process for the preparation thereof
US20090318695A1 (en) *	2008-06-19	2009-12-24	Vinod Kumar Kansal	Processes for the preparation of varenicline and intermediates thereof
US20100010221A1 (en) *	2008-07-10	2010-01-14	Revital Lifshitz-Liron	Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
EP2334679A1 (en) *	2008-09-01	2011-06-22	Actavis Group PTC EHF	Process for preparing varenicline, varenicline intermediates, and pharmaceutically acceptable salts thereof
EP2204369A1 (en)	2008-12-22	2010-07-07	Medichem, S.A.	Process for preparing varenicline and intermediates for use therein
KR20110132564A (en) *	2009-02-11	2011-12-08	선오비온 파마슈티컬스 인코포레이티드	Histamine H3 inverse agonists and antagonists, and methods of use thereof
WO2010143070A2 (en)	2009-06-10	2010-12-16	Actavis Group Ptc Ehf	Amorphous varenicline tartrate co-precipitates
EP2438054A1 (en)	2009-06-22	2012-04-11	Teva Pharmaceutical Industries Ltd.	Solid states forms of varenicline salts and processes for preparation thereof
EP2475664A2 (en) *	2009-09-11	2012-07-18	Sunovion Pharmaceuticals Inc.	Histamine h3 inverse agonists and antagonists and methods of use thereof
EP2545054A1 (en)	2010-03-09	2013-01-16	Actavis Group Ptc Ehf	Highly pure varenicline or a pharmaceutically acceptable salt thereof substantially free of methylvarenicline impurity
KR101109389B1 (en) *	2010-04-30	2012-01-30	삼성전기주식회사	Printed circuit board and manufacturing method thereof
WO2011140431A1 (en)	2010-05-06	2011-11-10	Teva Pharmaceutical Industries Ltd.	Varenicline salts and crystal forms thereof
US20120004239A1 (en)	2010-06-11	2012-01-05	Medichem, S.A.	Process for Preparing Quinoxaline Derivatives
RU2014103098A (en)	2011-06-30	2015-08-10	Торэй Индастриз, Инк.	ANTI-EXPLOSIVE AGENT
ITMI20111413A1 (en) *	2011-07-28	2013-01-29	Dipharma Francis Srl	PROCEDURE FOR THE PREPARATION OF VARENICLINA
ES2426838B1 (en)	2012-04-20	2014-05-07	Genetracer Biotech S.L	Method to predict success in quitting tobacco use in response to drug treatment
ES2426517B1 (en)	2012-04-20	2014-05-14	Genetracer Biotech S.L	Method to predict the safety of a drug treatment
CN103570502A (en) *	2012-07-18	2014-02-12	上海科胜药物研发有限公司	Preparation method for varenicline intermediate
US9636340B2 (en)	2013-11-12	2017-05-02	Ayyappan K. Rajasekaran	Kinase inhibitors
CN103992272B (en) *	2014-06-09	2016-05-11	安徽省逸欣铭医药科技有限公司	A kind of pentazocine hydrochloride ester, Its Preparation Method And Use
KR20160126697A (en)	2015-04-24	2016-11-02	한미정밀화학주식회사	Novel crystalline varenicline oxalate hydrate, preparation method thereof, and pharmaceutical composition comprising same
KR20160143407A (en)	2015-06-05	2016-12-14	한미정밀화학주식회사	Novel varenicline mucate, crystalline form thereof, and method of preparation thereof
KR101724301B1 (en)	2016-11-22	2017-04-10	주식회사 한서켐	Novel crystal form I of varenicline salicylate and its preparing method
CN106674194B (en) *	2016-12-14	2019-03-05	山东省联合农药工业有限公司	A kind of nicotinic insecticide of structure novel and its preparation method and application
WO2018160043A1 (en)	2017-03-03	2018-09-07	주식회사 씨티씨바이오	Preparation, comprising inclusion complex of varenicline or pharmaceutically acceptable salt thereof, for oral administration
KR102463733B1 (en)	2017-06-30	2022-11-04	한미약품 주식회사	Pharmaceutical composition comprising Varenicline Oxalate with improved content uniformity and stability
WO2018154395A2 (en)	2018-06-11	2018-08-30	Alvogen Malta Operations (Row) Ltd	Controlled release pharmaceutical composition of varenicline
KR20200034293A (en)	2018-09-21	2020-03-31	한미약품 주식회사	Varenicline formulation for controlled-release
EP4142734B1 (en)	2020-04-28	2025-08-20	Oyster Point Pharma, Inc.	Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections
CN113956255A (en) *	2020-07-20	2022-01-21	威智医药有限公司	Preparation method of varenicline intermediate, varenicline and salt thereof
US11040983B1 (en)	2020-08-14	2021-06-22	Almatica Pharma Llc	Cocrystal of varenicline and oxalic acid, pharmaceutical composition thereof, and methods of use thereof
WO2022035434A1 (en)	2020-08-14	2022-02-17	Almatica Pharma Llc	Cocrystal of varenicline and oxalic acid, pharmaceutical composition thereof, and methods of use thereof
WO2022147189A1 (en) *	2020-12-30	2022-07-07	Antares Pharma, Inc.	Varenicline prodrugs
WO2022222019A1 (en) *	2021-04-20	2022-10-27	Suzhou Fude Zhaofeng Biochemical Technology Co., Ltd	Total synthesis of varenicline
CN113277993B (en) *	2021-06-06	2023-07-21	湖南第一师范学院	A kind of synthetic method of Tafamidis and derivative thereof
WO2023275413A2 (en)	2021-12-23	2023-01-05	Medichem, S.A.	Solid pharmaceutical formulations of varenicline
US11602537B2 (en)	2022-03-11	2023-03-14	Par Pharmaceutical, Inc.	Varenicline compound and process of manufacture thereof
EP4241775A1 (en)	2022-03-11	2023-09-13	Par Pharmaceutical, Inc.	Tablet comprising varenicline and process of preparation thereof
WO2023244574A1 (en)	2022-06-14	2023-12-21	Amygdala Neurosciences, Inc.	Aldh-2 inhibitor compounds and methods of use
WO2024095172A1 (en)	2022-11-04	2024-05-10	Pfizer Inc.	Prodrugs of varenicline and compounds containing vulnerable amines
IT202300003888A1 (en)	2023-03-03	2024-09-03	Dipharma Francis Srl	PROCESS OF PREPARING A MEDICATION USED TO TREAT NICOTINE ADDICTION
WO2024224270A1 (en)	2023-04-24	2024-10-31	Pfizer Inc.	Varenicline formulations

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3471503A (en) *	1967-05-05	1969-10-07	Mcneilab Inc	1,2,3,5,6,7-hexahydro-4-phenethyl-2,6-methano-4h-4- benzazonin-12-ols
CH644116A5 (en) *	1980-08-21	1984-07-13	Hoffmann La Roche	IMIDAZOLE DERIVATIVES.
EP0853621A1 (en) *	1995-09-22	1998-07-22	Novo Nordisk A/S	Novel substituted azacyclic or azabicyclic compounds
US6605610B1 (en) *	1997-12-31	2003-08-12	Pfizer Inc	Aryl fused azapolycyclic compounds
ME00459B (en) *	1997-12-31	2011-10-10	Pfizer Prod Inc	Aryl fused azapolycyclic compounds
AU1918299A (en) *	1998-02-23	1999-09-06	Warner-Lambert Company	Substituted quinoxaline derivatives as interleukin-8 receptor antagonists
EP0955301A3 (en) *	1998-04-27	2001-04-18	Pfizer Products Inc.	7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors
US6462035B1 (en) *	1998-04-29	2002-10-08	Pfizer Inc.	Aryl fused azapolycyclic compounds
NZ512884A (en) *	1999-01-29	2004-03-26	Abbott Lab	Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands
FR2788982B1 (en) *	1999-02-02	2002-08-02	Synthelabo	PHARMACEUTICAL COMPOSITIONS CONTAINING NICOTINE AND THEIR APPLICATION IN SMOKING WITHDRAWAL
IL137937A0 (en) *	1999-08-27	2001-10-31	Pfizer Prod Inc	A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
NZ528209A (en) *	2001-05-14	2004-09-24	Pfizer Prod Inc	The citrate salt of 5, 8, 14-triazatetracyclo (10.3.1.02,11.04.9)-hexadeca-2.(11),3,5,7,9-pentaene
PT1392307E (en) *	2001-05-14	2005-11-30	Pfizer Prod Inc	SALTS 5,8,14-TRIAZATETRACYCLO [10.3.1.02,11.04,9] -HEXADECA-2 (11), 3,5,7,9-PENTAENE
DE60209929T2 (en) *	2001-11-29	2006-11-16	Pfizer Products Inc., Groton	SUCCINATE SALTS OF 58; 8; 14-TRIATETRACYCLO [10.3.1.0 2,11 .0 4,9] -HEXADECA-2,11,3,5,7,9-PENTAES AND PHARMACEUTICAL COMPOSITIONS
RU2004116320A (en) *	2001-11-30	2005-10-10	Пфайзер Продактс Инк. (Us)	Aryl-condensed azapolycyclic compounds
PT1448235E (en) *	2001-11-30	2007-05-31	Pfizer Prod Inc	Oral controlled release pharmaceutical compositions of 5,8,14-triazatetracyclo 10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene
JP2006528170A (en) *	2003-07-21	2006-12-14	ファイザー・プロダクツ・インク	Aryl-fused azapolycyclic compounds

1998
- 1998-11-13 ME MEP-2008-702A patent/ME00459B/en unknown
- 1998-11-13 EP EP05106853A patent/EP1659114A3/en not_active Withdrawn
- 1998-11-13 ES ES98950274.5T patent/ES2301210T5/en not_active Expired - Lifetime
- 1998-11-13 CN CNA2005100821428A patent/CN1715280A/en active Pending
- 1998-11-13 NZ NZ504482A patent/NZ504482A/en not_active IP Right Cessation
- 1998-11-13 BR BRPI9816186-5A patent/BR9816186B1/en not_active IP Right Cessation
- 1998-11-13 HR HR20000445A patent/HRP20000445B1/en not_active IP Right Cessation
- 1998-11-13 CZ CZ20002438A patent/CZ301925B6/en not_active IP Right Cessation
- 1998-11-13 IL IL13672798A patent/IL136727A0/en active Protection Beyond IP Right Term
- 1998-11-13 US US09/402,010 patent/US6410550B1/en not_active Expired - Lifetime
- 1998-11-13 EP EP98950274.5A patent/EP1044189B2/en not_active Expired - Lifetime
- 1998-11-13 KR KR10-2000-7007379A patent/KR100408138B1/en not_active Expired - Lifetime
- 1998-11-13 AU AU96416/98A patent/AU753389C/en not_active Expired
- 1998-11-13 UA UA2000063807A patent/UA66825C2/en unknown
- 1998-11-13 DE DE69839131.4T patent/DE69839131T3/en not_active Expired - Lifetime
- 1998-11-13 HU HU0100949A patent/HU230297B1/en active Protection Beyond IP Right Term
- 1998-11-13 CN CNB988128195A patent/CN1324013C/en not_active Expired - Lifetime
- 1998-11-13 PL PL341824A patent/PL209404B1/en unknown
- 1998-11-13 SI SI9830902T patent/SI1044189T2/en unknown
- 1998-11-13 WO PCT/IB1998/001813 patent/WO1999035131A1/en not_active Ceased
- 1998-11-13 EA EA200000592A patent/EA003190B1/en not_active IP Right Cessation
- 1998-11-13 DK DK98950274T patent/DK1044189T4/en active
- 1998-11-13 CA CA002316921A patent/CA2316921C/en not_active Expired - Lifetime
- 1998-11-13 SK SK971-2000A patent/SK286886B6/en not_active IP Right Cessation
- 1998-11-13 DE DE122008000038C patent/DE122008000038I1/en active Pending
- 1998-11-13 JP JP2000527532A patent/JP3550359B2/en not_active Expired - Lifetime
- 1998-11-13 PT PT98950274T patent/PT1044189E/en unknown
- 1998-11-13 AT AT98950274T patent/ATE386024T1/en active
- 1998-11-13 RS YUP-403/00A patent/RS50069B/en unknown
- 1998-11-13 TR TR2000/01840T patent/TR200001840T2/en unknown
- 1998-11-13 BR BRPI9814592-4A patent/BR9814592B1/en not_active IP Right Cessation
- 1998-11-13 SG SG200203917A patent/SG102686A1/en unknown
- 1998-11-13 HR HR20050506A patent/HRP20050506A2/en not_active Application Discontinuation
- 1998-11-19 HN HN1998000177A patent/HN1998000177A/en unknown
- 1998-11-30 CO CO98070723A patent/CO4810373A1/en unknown
- 1998-11-30 PA PA19988463901A patent/PA8463901A1/en unknown
- 1998-12-15 GT GT199800200AK patent/GT199800200AA/en unknown
- 1998-12-15 GT GT199800200A patent/GT199800200A/en unknown
- 1998-12-17 AP APAP/P/1998/001422A patent/AP1170A/en active
- 1998-12-28 EG EG161298A patent/EG23816A/en active
- 1998-12-28 PE PE1998001286A patent/PE20000053A1/en not_active IP Right Cessation
- 1998-12-28 TW TW087121748A patent/TW513412B/en not_active IP Right Cessation
- 1998-12-29 AR ARP980106715A patent/AR017967A1/en active IP Right Grant
- 1998-12-29 ZA ZA9811911A patent/ZA9811911B/en unknown
- 1998-12-30 TN TNTNSN98237A patent/TNSN98237A1/en unknown
- 1998-12-30 MY MYPI98005949A patent/MY118163A/en unknown
- 1998-12-30 DZ DZ980307A patent/DZ2697A1/en active
- 1998-12-30 MA MA25409A patent/MA26589A1/en unknown
1999
- 1999-02-28 SA SA99191123A patent/SA99191123B1/en unknown
2000
- 2000-05-26 IS IS5514A patent/IS5514A/en unknown
- 2000-06-12 IL IL136727A patent/IL136727A/en active Protection Beyond IP Right Term
- 2000-06-16 OA OA1200000175A patent/OA11428A/en unknown
- 2000-06-27 BG BG104561A patent/BG65058B1/en unknown
- 2000-06-30 NO NO20003422A patent/NO319115B1/en not_active IP Right Cessation
2002
- 2002-02-13 US US10/075,843 patent/US6887884B2/en not_active Expired - Fee Related
- 2002-02-14 US US10/075,348 patent/US20020072524A1/en not_active Abandoned
- 2002-04-22 US US10/127,267 patent/US6951938B2/en not_active Expired - Lifetime
- 2002-04-23 US US10/131,278 patent/US6897310B2/en not_active Expired - Lifetime
2006
- 2006-11-17 NO NO2006016C patent/NO2006016I1/en not_active IP Right Cessation
2007
- 2007-07-17 US US11/778,890 patent/US20070275973A1/en not_active Abandoned
2008
- 2008-04-14 CY CY20081100397T patent/CY1107391T1/en unknown
- 2008-05-21 LU LU91442C patent/LU91442I2/en unknown
- 2008-06-05 NL NL300355C patent/NL300355I2/en unknown
- 2008-07-03 CY CY200800013C patent/CY2008013I1/en unknown
- 2008-07-21 FR FR08C0039C patent/FR08C0039I2/en active Active
2016
- 2016-04-27 HU HUS1600018C patent/HUS1600018I1/en unknown

Also Published As

Publication number	Publication date
AP1170A (en)	2003-06-30
KR20010033823A (en)	2001-04-25
HRP20050506A2 (en)	2006-03-31
GT199800200A (en)	2000-06-07
PA8463901A1 (en)	2000-09-29
DK1044189T3 (en)	2008-05-13
PE20000053A1 (en)	2000-02-07
US6951938B2 (en)	2005-10-04
CA2316921A1 (en)	1999-07-15
IS5514A (en)	2000-05-26
DE122008000038I1 (en)	2008-11-13
AU753389C (en)	2007-08-09
PL209404B1 (en)	2011-08-31
OA11428A (en)	2004-05-03
BG104561A (en)	2001-01-31
NL300355I1 (en)	2008-08-01
NO20003422L (en)	2000-08-29
US6410550B1 (en)	2002-06-25
US20020111350A1 (en)	2002-08-15
ES2301210T3 (en)	2008-06-16
ES2301210T5 (en)	2015-05-07
IL136727A (en)	2006-06-11
DK1044189T4 (en)	2015-03-30
AR017967A1 (en)	2001-10-24
DE69839131T3 (en)	2015-05-07
PL341824A1 (en)	2001-05-07
NO319115B1 (en)	2005-06-20
CN1715280A (en)	2006-01-04
EA200000592A1 (en)	2000-12-25
EP1044189B1 (en)	2008-02-13
FR08C0039I1 (en)	2008-11-14
EA003190B1 (en)	2003-02-27
NO2006016I2 (en)	2008-10-20
AU9641698A (en)	1999-07-26
HUP0100949A3 (en)	2002-12-28
EP1044189A1 (en)	2000-10-18
CY1107391T1 (en)	2010-07-28
US6887884B2 (en)	2005-05-03
NZ504482A (en)	2003-01-31
YU40300A (en)	2003-10-31
SI1044189T2 (en)	2015-05-29
CN1324013C (en)	2007-07-04
HU230297B1 (en)	2015-12-28
SI1044189T1 (en)	2008-06-30
JP3550359B2 (en)	2004-08-04
US6897310B2 (en)	2005-05-24
NL300355I2 (en)	2008-11-03
CO4810373A1 (en)	1999-06-30
TW513412B (en)	2002-12-11
HN1998000177A (en)	1999-02-09
CY2008013I2 (en)	2009-11-04
PT1044189E (en)	2008-04-22
GT199800200AA (en)	2000-06-07
AP9801422A0 (en)	1998-12-31
EG23816A (en)	2007-09-19
LU91442I2 (en)	2008-07-21
UA66825C2 (en)	2004-06-15
HK1031878A1 (en)	2001-06-29
ATE386024T1 (en)	2008-03-15
EP1044189B2 (en)	2015-02-25
DZ2697A1 (en)	2003-03-29
BR9814592B1 (en)	2010-06-01
SA99191123B1 (en)	2006-10-02
MY118163A (en)	2004-09-30
CZ20002438A3 (en)	2002-11-13
HRP20000445A2 (en)	2001-04-30
HUP0100949A2 (en)	2001-08-28
IL136727A0 (en)	2001-06-14
ZA9811911B (en)	2000-06-29
KR100408138B1 (en)	2003-12-01
DE69839131T2 (en)	2009-02-05
BG65058B1 (en)	2007-01-31
ME00459B (en)	2011-10-10
AU753389B2 (en)	2002-10-17
US20020072524A1 (en)	2002-06-13
CN1285821A (en)	2001-02-28
HUS1600018I1 (en)	2018-05-02
CA2316921C (en)	2004-12-07
TNSN98237A1 (en)	2005-03-15
LU91442I9 (en)	2018-12-31
MA26589A1 (en)	2004-12-20
WO1999035131A1 (en)	1999-07-15
HRP20000445B1 (en)	2009-04-30
CY2008013I1 (en)	2009-11-04
TR200001840T2 (en)	2000-12-21
JP2002500218A (en)	2002-01-08
US20020132824A1 (en)	2002-09-19
BR9816186B1 (en)	2009-01-13
NO2006016I1 (en)	2006-11-27
SK9712000A3 (en)	2002-03-05
RS50069B (en)	2009-01-22
EP1659114A3 (en)	2007-01-17
DE69839131D1 (en)	2008-03-27
CZ301925B6 (en)	2010-08-04
NO20003422D0 (en)	2000-06-30
SK286886B6 (en)	2009-07-06
EP1659114A2 (en)	2006-05-24
US20070275973A1 (en)	2007-11-29
US20020072525A1 (en)	2002-06-13
BR9814592A (en)	2000-10-17
SG102686A1 (en)	2004-03-26

Publication	Publication Date	Title
FR08C0039I2 (en)	2009-12-18	AZAPOLYCYCLIC COMPOUNDS FUSED WITH AN ARYL
DE69719705D1 (en)	2003-04-17	toner cartridge
MX220140B (en)	2004-04-28	BENZOIL DERIVATIVES SUBSTITUTED WITH 3-HETEROCICLYL
DE69822940D1 (en)	2004-05-13	Antistatic thermoplastic blend
MA24580A1 (en)	1998-12-31	DIPEPTIDE COMPOUNDS
NO996283D0 (en)	1999-12-17	Multimode Straight Receiver
DE69831198D1 (en)	2005-09-22	Toner reservoir
DE69935516D1 (en)	2007-04-26	ANTIBODIES WITH IMPROVED PRODUCTABILITY
DE69720156D1 (en)	2003-04-30	toner cartridge
MA26467A1 (en)	2004-12-20	COMPOUNDS INHIBITING METALLOPROTEASES.
DE69724929D1 (en)	2003-10-23	toner cartridge
DE69727900D1 (en)	2004-04-08	toner cartridge
IT1291210B1 (en)	1998-12-29	ANTI-STATIC TIRE.
EP1087957A4 (en)	2003-01-02	SELF-INDUCING COMPOUNDS
DE69817039D1 (en)	2003-09-18	toner cartridge
NO996354D0 (en)	1999-12-20	Peripherally acting anti-pruritic opiates
DE69720936D1 (en)	2003-05-22	toner cartridge
DE69841297D1 (en)	2010-01-07	toner
DE69716690D1 (en)	2002-12-05	toner replenishment
DE69817659D1 (en)	2003-10-09	toner container
DE69928527D1 (en)	2005-12-29	TONER
DK0862197T3 (en)	1999-11-15	Fused Connection
MA24499A1 (en)	1998-10-01	NEW COMPOUNDS
DE69715988D1 (en)	2002-11-07	toner cartridge
DE69815048D1 (en)	2003-07-03	COPIER